Multiple sclerosis (MS) and Neuromyelitis Optica (NMO) are both demyelinating disorders and oxidative stress is suggested to have a role in their pathogenesis. Glucose 6 phosphate dehydrogenase (G6PD) produces nicotinamide adenine dinucleotide phosphate (NADPH) via the pentose phosphate pathway. NADPH is not only involved in the synthesis of fatty acids necessary for myelination but also it is involved in the defense against oxidative stress. Prescribing Supplementary Vitamin D as a part of the MS treatment plan can increase G6PD gene expression. The aim of this study is to determine the serum level of G6PD in MS and NMO patients and its relationship with vitamin D since it is yet to be explored thoroughly.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
© 2019 Published by Elsevier Inc.